Abstract

Objectives: The aim of this study was to make a comprehensive economic assessment of the costs of hospital-acquired C. difficile infections (CDI).Methods: We carried out a retrospective matched cohort study utilizing Danish registry data with national coverage to identify CDI cases and matched reference patients without CDI (controls) for economic burden assessment in Denmark covering 2011–2014. Health care costs and public transfer costs were obtained from national registries, and calculated for 1 year prior to, and 2 years after index admission using descriptive statistics and regression analysis.Results: The study included 12,768 CDI patients and 23,272 matched controls. The total health care cost was significantly larger for CDI cases than controls throughout all periods. During the index admission period, cost was €12,867 per CDI case compared to €4,522 (p < 0.001) for controls, which increased to an average of €31,388 and €19,512 (p < 0.001) in Year 1 for the two groups, respectively. Excess costs were found both among infections with onset in hospitals and in the community. Diagnosis compatible with complications increased costs to on average >€91,000 per case. The regression analysis showed that CDI adds a substantial economic burden, but only explains about 1/3 of the crude difference observed in the matched analysis.Discussion: The major economic impact of hospital-acquired CDI with complications underlines the importance of preventing complications in these patients. Our study provides an informed estimate of the potential economic gain per patient by successful intervention, which is likely to be relatively comparable across countries.

Highlights

  • Clostridioides difficile is the leading cause of infectious diarrhea in hospitalized patients [1], and occurs regardless of economic development [2, 3]

  • This hypothesis is corroborated by data from the national surveillance in Denmark (HAIBA annual report 2018, https://www.ssi.dk/-/ media/arkiv/subsites/miba-og-haiba/dokument/haiba_2018rsrapport.pdf?la=da), and this possible trend highlights the need for differentiation of the cost estimations for healthcare-onset hospital-acquired (HOHA) and community-onset hospital-acquired (COHA) C. difficile infection (CDI)

  • Even with a careful matching procedure based on underlying disease codes, cases of CDI had an excess of severe illness and were hospitalized longer, and had higher frequencies of inflammatory bowel disease (IBD) before index date

Read more

Summary

Introduction

Clostridioides difficile is the leading cause of infectious diarrhea in hospitalized patients [1], and occurs regardless of economic development [2, 3]. With the contemporary change in treatment paradigm toward shorter periods of hospitalization and more patients treated in ambulatory care, a change in the epidemiology of CDI with a shift from HOHA to COHA CDI would be expected [8]. This hypothesis is corroborated by data from the national surveillance in Denmark (HAIBA annual report 2018, https://www.ssi.dk/-/ media/arkiv/subsites/miba-og-haiba/dokument/haiba_2018rsrapport.pdf?la=da), and this possible trend highlights the need for differentiation of the cost estimations for HOHA and COHA CDI. The aim of the present study was to assess the economic burden attributable to CDI during and after hospitalization for both HOHA and COHA CDI, using a population based matched cohort design

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call